Denise Neves Gameiro, Author at Labiotech.eu - Page 7 of 24

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

oxitec aedes aegypti grand cayman zika dengue

News and Trends 1 Aug 2016

The Cayman Islands will now also release GM Mosquitoes against Zika Virus

A court finally allowed the release of Oxitec‘s ‘friendly’ mosquitoes in the Grand Cayman (1 of the 3 islands). If the technique repeats its recent successes, the local population of Zika-transmitting species could decrease by 90%. Located in the tropics, the Cayman Islands are one of the territories at risk of the spread of Aedes […]

August 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

gene therapy hemophilia fix uniqure

News and Trends 29 Jul 2016

Gene Therapy for severe Hemophilia has new Phase I/II Results

uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia B, a rare genetic disorder. After 9 months, the therapy maintains 75% reduction of transfusions. A good sign for the therapy’s durability. Although quite rare (1 in 20,000 male births), Hemophilia B is famous for being spread in European royal […]

July 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

selective nanopore sequencing real time ngs

News and Trends 28 Jul 2016

Pocket NGS can now select DNA fragments for faster Sequencing

Researchers from the University of Nottingham have developed a way to select which DNA to sequence with the pocket-sized MinION. The new feature speeds up on-the-spot, real-time DNA sequencing. Developed by the billion-euro Biotech Oxford Nanopore (UK), the small MinION may not have the accuracy and speed of normal laboratory machines for next generation sequencing (NGS). But […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

taurx tau protein tangles biotech alzheimers

News and Trends 28 Jul 2016

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

The much-anticipated results of TauRx’s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients. According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

nootkatone evolva natural mosquito repellant zika

News and Trends 27 Jul 2016

SynBio Nootkatone now in trials to stop the Spread of Zika

The grapefruit aroma nootkatone is now in field trials to assess its effectiveness against mosquitoes that spread the Zika virus. Good news for Evolva, which figured out a SynBio process to produce the compound. Recently, the Zika went from being considered a mild virus to a public health emergency. As the virus was linked with infant microcephaly, there […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

mrna astrazeneca cardiometabolic diseases moderna

News and Trends 27 Jul 2016

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

liver hepatitis c gilead vaccine HCV metavax

News and Trends 27 Jul 2016

New Vaccine could solve the problem of the costly Gilead’s Hepatitis C ‘Cure’

Artes Biotechnology and Burnet Institute will join their proprietary technologies to develop a novel vaccine for the Hepatitis C virus. This could create a more affordable solution to reduce the high HCV-related mortality. Hepatitis C remains a health problem around the world. WHO estimates that more than half a million people die every year from […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

cancer hypoxia antimalarial drug atovaquone

News and Trends 26 Jul 2016

This Malaria drug is being re-purposed for Cancer Radiotherapy

Cancer Research UK says an old anti-malaria drug could be repurposed as a cancer therapy. In pre-clinical studies, this drug increases oxygen levels in tumors, making them easier to treat with radiotherapy. Atovaquone has been on the market since 2000 as part of an anti-malarial drug. It is also commercialized by GSK under the name Mepron for […]

July 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

boehringer ingelheim stroke thrombus ischamia agels europe

News and Trends 21 Jul 2016

Biotech-funded ‘Angels Initiative’ wants to create 1500 Stroke centres across Europe

Boehringer Ingelheim is funding a new initiative to tackle stroke in Europe, a leading cause of disability and death. Together with the European Stroke Organisation, it aims to have 1500 new stroke-ready centres by 2019. Cardiovascular diseases are now the #1 cause of death all over the world, killing an estimated 17.5 million people according to the […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

gensight biologics ipo euronext gene therapy

News and Trends 21 Jul 2016

UPDATED: French Gene Therapy for Blindness Launches another IPO

Update (21/07/2016): Gensight has successfully completed its IPO, raising €40M. This brings the Biotech’s total market capitalization to near €149M. The option of round oversubscription to €46M is still open. Originally published on 5/7/2016 After canceling its NASDAQ IPO back in April, GenSight is now launching on the Euronext Paris. It wants to raise €40M in total, […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

hookipa biotech vaccine vaxwave hcmv

News and Trends 21 Jul 2016

Former uniQure and Evotec CEO pushes new viral candidate into Clinical Trials

Hookipa is starting its first clinical trial for a vaccine against human cytomegalovirus. This is the leading candidate of its platform for novel viral vectors, which promises to yield better vaccines for infections and cancer. Based in Vienna, Hookipa was founded in 2011 and is developing a new class of immunotherapies. Its strategy for novel […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT